The International Society on Thrombosis and Homeostasis (ISTH) is holding its annual Congress in Montreal, June 24 – 28, and Aegros will be there to present two research papers to the assembled practitioners and experts.
In this update, we’ll look at one of those research papers titled Plasma Fractionation by HaemaFrac® Technology – A Bioprocessing Innovation.
The background to this paper rests on the importance of passive immunity as a means of disease prevention.
Traditional methods of passing on passive immunity to patients have included monoclonal antibodies and convalescent plasma; however with SARS-CoV-2 and Covid-19, monoclonal antibodies have proven ineffectual and convalescent plasma contains a very broad spectrum of polyclonal antibodies. Aegros and the HaemaFrac® have made a new method of passive immunity available in the fight against SARS-CoV-2 by concentrating convalescent plasma to manufacture a hyperimmune against Covid-19.
HaemaFrac® processing of Covid-19 convalescent plasma has produced a hyperimmune product with a higher yield, compared to Cohn plasma fractionation.
Fractionation by HaemaFrac® also enables the retention of immunoglobulin sub-classes at levels present in the source convalescent plasma, including maintenance of physiological levels of IgG3 which is traditionally lost through the process of Cohn fractionation. IgG3 is a plasma sub-type that plays a highly important role in anti-viral responses.
The Aegros SARS-CoV-2 hyperimmune solves the problem left in the wake of the declining effectiveness of monoclonal antibodies, and concentrates the effectiveness of convalescent plasma, thereby providing therapists with an advantage over the other forms of transferring passive immunity against Covid-19.
Through this paper, the HaemaFrac® has shown its success in creating a hyperimmune product during a time of pandemic, establishing also the usefulness of Aegros’ technology to prepare effective hyperimmunes in general whenever they are required.
The paper is authored by members of the Aegros Research & Development team; including Brian Saputro, Chrys Maoudis, Zeena Amini, Grace Crossland, Nadia Rahi, Stephen Mahler, John Foster and Hari Nair.
Congratulations to all of these Aegros scientists and researchers.
The paper will be displayed to Congress attendees and Aegros Chief Medical Officer, Dr Leon Rosen, will be in Montreal to discuss its methods, results, and conclusions with leading medical practitioners.
In an article later this week, Aegros will discuss the second of its research papers that will be presented at ISTH 2023.
Aegros looks forward to seeing colleagues at ISTH 2023 and hopes that all delegates enjoy the learning opportunities the conference offers.